Peptide Drug Conjugates Market to Grow with a CAGR of 13.32% through 2028
Increasing demand for targeted therapies, and advancements in peptide
engineering is expected to drive the Global Peptide Drug Conjugates Market growth
in the forecast period, 2024-2028.
According to
TechSci Research report, “Peptide Drug Conjugates Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2028”,
the Global Peptide Drug Conjugates Market stood at USD 600.01 billion in 2022 and
is anticipated to grow with a CAGR of 13.32% in the forecast period, 2024-2028.
Peptide drug conjugates (PDCs) have emerged as a promising class of drugs that
combine the precision of peptides with the potency of cytotoxic agents,
offering a revolutionary approach to treating various diseases, notably cancer.
This market is witnessing significant growth driven by the pressing need for
more effective and less toxic treatment options. With cancer incidence on the
rise globally, PDCs have garnered considerable attention for their ability to
precisely target malignant cells, sparing healthy tissues and mitigating
debilitating side effects associated with traditional chemotherapy.
The rising incidence of cancer has not only underscored the urgent need
for better treatment options but has also served as a driving force behind the
Peptide Drug Conjugates Market's remarkable growth. PDCs' ability to
specifically target cancer cells while sparing healthy tissues aligns perfectly
with the aspirations of modern medicine for personalized and precision
therapies. Furthermore, advancements in polymer-based drug delivery systems
have enabled the development of PDCs with customizable release profiles,
allowing for sustained therapeutic effects over extended periods. Such control
over drug release kinetics is particularly advantageous in treating chronic
diseases and conditions.These innovations in drug delivery technologies have
not only elevated the precision and efficiency of PDCs but have also expanded
their potential applications beyond oncology. PDCs are now being explored for
the treatment of autoimmune diseases, infectious diseases, and other
therapeutic areas where targeted delivery of therapeutic agents is paramount.The
increased interest in targeted therapies has led to a surge in research and
development efforts focused on PDCs. Pharmaceutical companies, academic
institutions, and biotechnology firms are actively exploring the potential of
PDCs across various disease areas, including oncology, autoimmune disorders,
and infectious diseases. As a result, the PDC pipeline is expanding rapidly,
with numerous candidates in various stages of preclinical and clinical
development.
Browse over XX market data Figures spread through XX Pages and an
in-depth TOC on
"Global Peptide Drug Conjugates Market.”
In addition to
oncology, the expanding pipeline of peptide-based drugs extends to other
critical disease areas, including autoimmune disorders, infectious diseases,
and neurodegenerative conditions. This robust pipeline reflects the industry's
confidence in the efficacy and safety of PDCs, further boosting their market
presence. Peptide drug conjugates are a type of targeted therapy, which means
that they are designed to specifically target cancer cells. This makes them
more effective and less likely to cause side effects than traditional
therapies. The pipeline of peptide-based drugs is also expanding due to the
development of new technologies for the conjugation of peptides and drugs.
These technologies are making it possible to create peptide drug conjugates
that are more stable and have a longer half-life. This makes them more
effective and suitable for a wider range of applications.
The Global Peptide Drug Conjugates Market is segmented into Product, Type,
regional distribution, and company.
Based on product, the Global Peptide Drug Conjugates Market is segmented
into Lutetium, Melflufen, ANG1005, BT1718, CBX-12 and Other
Pipeline Products. Based on the Product,
the Lutathera segment emerged as the dominant player in the global market for
Peptide Drug Conjugates in 2022.This is attributed to several factors including that Lutathera has demonstrated clinical
success in multiple trials, showing significant improvement in progression-free
survival and quality of life for patients with this rare form of cancer.
Regulatory approvals from major agencies, such as the FDA and EMA, have
provided Lutathera with a strong foothold in the market, allowing it to be
prescribed by healthcare providers with confidence. Neuroendocrine tumors are often difficult to
treat, and there are limited effective therapeutic options available.
Lutathera's ability to specifically target and destroy tumor cells with minimal
damage to healthy tissue has positioned it as a breakthrough treatment in this
space. Patients and physicians are increasingly turning to Lutathera as a
valuable treatment option, contributing to its dominant market position. Lutathera's manufacturer has expanded its
distribution and availability across multiple regions, ensuring that patients
worldwide have access to this treatment.
Based on type, the Global Peptide Drug Conjugates Market is segmented
into Therapeutic , and Diagnostic. Based
on the type, the therapeutic segment emerged as the dominant player in the
global market for Peptide Drug Conjugates in 2022. This is attributed to
several key factors including clinical applications, oncology dominance and
emerging treatment paradigms of Peptide Drug Conjugates in therapeutics. Within
the therapeutic PDC segment, oncology has been a significant driver. The
ability of PDCs to precisely target cancer cells while sparing healthy tissues
is a game-changer in cancer treatment. As cancer continues to be a leading
cause of mortality worldwide, there is a growing demand for more effective and
less toxic therapies, which therapeutic PDCs can provide.The pharmaceutical
industry is witnessing a shift towards targeted therapies and personalized
medicine. Therapeutic PDCs align perfectly with these emerging treatment
paradigms, as they can be customized to target specific disease markers or
genetic mutations in individual patients.
North America emerged as the dominant player in the global Peptide Drug
Conjugates market in 2022, holding the largest market share. This is on account
of several key factors such as advanced healthcare infrastructure, Strong
Research and Development Ecosystem and high regulatory acceptance. North
America boasts a well-developed and advanced healthcare infrastructure,
comprising state-of-the-art medical facilities, research institutions, and
pharmaceutical companies. This infrastructure provides a conducive environment
for the development, clinical testing, and commercialization of innovative
therapies like PDCs.
Major companies operating in Global Peptide Drug Conjugates Market are:
- Novartis AG.
- Bicycle Therapeutics
PLC
- AstraZeneca PLC
- Cybrexa Therapeutics
Inc
- Oncopeptides Inc.
- Angiochem Inc.
- Innovasium Soricimed
Biopharma
- Theratechnologies Inc.
- Coherent Biopharma Co.
Ltd
- Wuxi STA
Download Free Sample Report
Customers can also request for 10% free customization on this report.
“The
increasing focus on personalized medicine. Peptide drug conjugates can be
designed to target specific molecules or cells, which makes them a good fit for
personalized medicine. The growing investment in the development of peptide
drug conjugates. Pharmaceutical companies and other investors are increasingly
investing in the development of these products. The favorable regulatory
environment. Besides, pharmaceutical companies and research institutions are
actively developing novel PDCs to address a wide range of diseases, including
cancer, autoimmune disorders, and infectious diseases. This growing pipeline
reflects the industry's confidence in the potential of PDCs as a therapeutic
modality. The regulatory environment for peptide drug conjugates is generally
favorable, which is helping to drive market growth.” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based management consulting
firm.
“Peptide Drug Conjugates
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
2018-2028 Segmented By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12,
Other Pipeline Products), By Type (Therapeutic, Diagnostic) By Region and Competition”, has evaluated the future growth potential
of Global Peptide Drug Conjugates Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Peptide Drug Conjugates Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email:
[email protected]
Website:https://www.techsciresearch.co